DaVita Net Change in Short-term Investments 2010-2025 | DVA
DaVita annual/quarterly net change in short-term investments history and growth rate from 2010 to 2025. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
- DaVita net change in short-term investments for the quarter ending March 31, 2025 was $-0.026B, a 780.86% increase year-over-year.
- DaVita net change in short-term investments for the twelve months ending March 31, 2025 was $-0.025B, a 129.18% decline year-over-year.
- DaVita annual net change in short-term investments for 2024 was $0.003B, a 95.66% decline from 2023.
- DaVita annual net change in short-term investments for 2023 was $0.063B, a 208.16% decline from 2022.
- DaVita annual net change in short-term investments for 2022 was $-0.058B, a 881.82% increase from 2021.
DaVita Annual Net Change in Short-term Investments
(Millions of US $) |
| 2024 |
$3 |
| 2023 |
$63 |
| 2022 |
$-58 |
| 2021 |
$-6 |
| 2020 |
$0 |
| 2019 |
$94 |
| 2018 |
$30 |
| 2017 |
$257 |
| 2016 |
$113 |
| 2015 |
$-79 |
| 2014 |
$-338 |
| 2013 |
$-8 |
| 2012 |
$10 |
| 2011 |
$43 |
| 2010 |
$1 |
| 2009 |
$8 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$10.978B |
$12.816B |
|
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
|
